Gelonghui, March 20 | Jilin Aodong (000623.SZ) said on the investor interactive platform that the company is developing, producing and selling a number of drugs in the fields of cancer, nephropathy, diabetes, cardiovascular and cerebrovascular diseases. Among them, injectable ribonucleic acid II is suitable for adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, lung cancer, breast cancer, soft tissue sarcoma and other cancers, and has a good effect on adjuvant treatment of hepatitis B. This product can also be used for other diseases caused by low immune function. Injectable Pingyangmycin hydrochloride treats head and neck scale cancers such as lip cancer, tongue cancer, gum cancer, and nasopharyngeal cancer. It can also be used to treat skin cancer, breast cancer, cervical cancer, esophageal cancer, penile cancer, vulvar cancer, malignant lymphoma, and necrotic granuloma. It also has certain curative effects on liver cancer. It has a significant curative effect on pterygium. Erlotinib hydrochloride tablets are suitable for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with sensitive mutations in the epidermal growth factor receptor (EGFR) gene, including first-line treatment, maintenance treatment, or second-line treatment after receiving at least one progression of chemotherapy in the past. Pibacilli capsules are suitable for locally advanced or metastatic breast cancer that is hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative, and should be used in combination with an aromatase inhibitor as the initial endocrine treatment for postmenopausal female patients. Sunitinib malate capsules are suitable for advanced renal cell carcinoma (RCC) that cannot be operated on. Renal rehabilitation tablets are used for heat and pain, acute nephritis edema, and acute attacks of chronic nephritis. Vildagliptin tablets are suitable for treating type 2 diabetes. In the cardiovascular and cerebrovascular fields, a large variety group has been created, with Xuefu Chuyu Oral Solution as the core. Key cultivating varieties include brainheart capsules for the treatment of coronary heart disease, myocardial infarction, cerebral arteriosclerosis, and cerebral thrombosis. Cardio-brain relief capsules for the treatment of hemiplegia, speech impairment, arteriosclerosis, and various diseases of high blood viscosity. Du Zhi pills, etc. used for qi ischemic ischemic stroke. The company is based on the pharmaceutical industry, implements a “large variety group, multi-variety group” sales promotion policy, and drug sales are progressing steadily.